Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab.
Identifieur interne : 000485 ( Main/Exploration ); précédent : 000484; suivant : 000486Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab.
Auteurs : Ashley M. Hopkins [Australie] ; Ganessan Kichenadasse [Australie] ; Elizabeth Garrett-Mayer [États-Unis] ; Christos S. Karapetis [Australie] ; Andrew Rowland [Australie] ; Michael J. Sorich [Australie]Source :
- Clinical cancer research : an official journal of the American Association for Cancer Research [ 1078-0432 ] ; 2020.
Abstract
PURPOSE
Immune checkpoint inhibitors (ICI) are a significant advance to the treatment of advanced non-small cell lung cancer (NSCLC); however, their initiation is associated with heterogeneity in outcomes. This study aimed to develop and validate a prognostic tool of survival in patients with advanced NSCLC treated with ICIs.
EXPERIMENTAL DESIGN
A pretreatment prognostic model was developed and validated using clinicopathologic data. Development data consisted of patients with advanced NSCLC treated with atezolizumab from the randomised trials OAK and POPLAR (
RESULTS
Pretreatment C-reactive protein (CRP) was the most predictive variable for OS. The prognostic tool was optimally defined by CRP, lactate dehydrogenase, derived neutrophil-to-lymphocyte ratio, albumin, PD-L1 expression, performance status, time since metastatic diagnosis, and metastatic site count. Prognostic groups had significantly different OS (
CONCLUSIONS
A prognostic tool was developed and validated to identify patient groups with distinctly different survival following atezolizumab initiation for advanced NSCLC.
DOI: 10.1158/1078-0432.CCR-19-2968
PubMed: 32086341
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab.</title><author><name sortKey="Hopkins, Ashley M" sort="Hopkins, Ashley M" uniqKey="Hopkins A" first="Ashley M" last="Hopkins">Ashley M. Hopkins</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia. ashley.hopkins@flinders.edu.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Kichenadasse, Ganessan" sort="Kichenadasse, Ganessan" uniqKey="Kichenadasse G" first="Ganessan" last="Kichenadasse">Ganessan Kichenadasse</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Flinders Medical Centre, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, Flinders Medical Centre, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Garrett Mayer, Elizabeth" sort="Garrett Mayer, Elizabeth" uniqKey="Garrett Mayer E" first="Elizabeth" last="Garrett-Mayer">Elizabeth Garrett-Mayer</name><affiliation wicri:level="2"><nlm:affiliation>American Society of Clinical Oncology, Alexandria, Virginia.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Virginie</region></placeName><wicri:cityArea>American Society of Clinical Oncology, Alexandria</wicri:cityArea></affiliation></author><author><name sortKey="Karapetis, Christos S" sort="Karapetis, Christos S" uniqKey="Karapetis C" first="Christos S" last="Karapetis">Christos S. Karapetis</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Flinders Medical Centre, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, Flinders Medical Centre, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Rowland, Andrew" sort="Rowland, Andrew" uniqKey="Rowland A" first="Andrew" last="Rowland">Andrew Rowland</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Sorich, Michael J" sort="Sorich, Michael J" uniqKey="Sorich M" first="Michael J" last="Sorich">Michael J. Sorich</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32086341</idno><idno type="pmid">32086341</idno><idno type="doi">10.1158/1078-0432.CCR-19-2968</idno><idno type="wicri:Area/Main/Corpus">000440</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000440</idno><idno type="wicri:Area/Main/Curation">000440</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000440</idno><idno type="wicri:Area/Main/Exploration">000440</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab.</title><author><name sortKey="Hopkins, Ashley M" sort="Hopkins, Ashley M" uniqKey="Hopkins A" first="Ashley M" last="Hopkins">Ashley M. Hopkins</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia. ashley.hopkins@flinders.edu.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Kichenadasse, Ganessan" sort="Kichenadasse, Ganessan" uniqKey="Kichenadasse G" first="Ganessan" last="Kichenadasse">Ganessan Kichenadasse</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Flinders Medical Centre, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, Flinders Medical Centre, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Garrett Mayer, Elizabeth" sort="Garrett Mayer, Elizabeth" uniqKey="Garrett Mayer E" first="Elizabeth" last="Garrett-Mayer">Elizabeth Garrett-Mayer</name><affiliation wicri:level="2"><nlm:affiliation>American Society of Clinical Oncology, Alexandria, Virginia.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Virginie</region></placeName><wicri:cityArea>American Society of Clinical Oncology, Alexandria</wicri:cityArea></affiliation></author><author><name sortKey="Karapetis, Christos S" sort="Karapetis, Christos S" uniqKey="Karapetis C" first="Christos S" last="Karapetis">Christos S. Karapetis</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Flinders Medical Centre, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, Flinders Medical Centre, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Rowland, Andrew" sort="Rowland, Andrew" uniqKey="Rowland A" first="Andrew" last="Rowland">Andrew Rowland</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Sorich, Michael J" sort="Sorich, Michael J" uniqKey="Sorich M" first="Michael J" last="Sorich">Michael J. Sorich</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author></analytic><series><title level="j">Clinical cancer research : an official journal of the American Association for Cancer Research</title><idno type="ISSN">1078-0432</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>PURPOSE</b></p><p>Immune checkpoint inhibitors (ICI) are a significant advance to the treatment of advanced non-small cell lung cancer (NSCLC); however, their initiation is associated with heterogeneity in outcomes. This study aimed to develop and validate a prognostic tool of survival in patients with advanced NSCLC treated with ICIs.</p></div><div type="abstract" xml:lang="en"><p><b>EXPERIMENTAL DESIGN</b></p><p>A pretreatment prognostic model was developed and validated using clinicopathologic data. Development data consisted of patients with advanced NSCLC treated with atezolizumab from the randomised trials OAK and POPLAR (</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Pretreatment C-reactive protein (CRP) was the most predictive variable for OS. The prognostic tool was optimally defined by CRP, lactate dehydrogenase, derived neutrophil-to-lymphocyte ratio, albumin, PD-L1 expression, performance status, time since metastatic diagnosis, and metastatic site count. Prognostic groups had significantly different OS (</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>A prognostic tool was developed and validated to identify patient groups with distinctly different survival following atezolizumab initiation for advanced NSCLC.</p></div></front></TEI><pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">32086341</PMID><DateRevised><Year>2020</Year><Month>07</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1078-0432</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>13</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title><ISOAbbreviation>Clin Cancer Res</ISOAbbreviation></Journal><ArticleTitle>Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab.</ArticleTitle><Pagination><MedlinePgn>3280-3286</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-19-2968</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Immune checkpoint inhibitors (ICI) are a significant advance to the treatment of advanced non-small cell lung cancer (NSCLC); however, their initiation is associated with heterogeneity in outcomes. This study aimed to develop and validate a prognostic tool of survival in patients with advanced NSCLC treated with ICIs.</AbstractText><AbstractText Label="EXPERIMENTAL DESIGN" NlmCategory="METHODS">A pretreatment prognostic model was developed and validated using clinicopathologic data. Development data consisted of patients with advanced NSCLC treated with atezolizumab from the randomised trials OAK and POPLAR (<i>n</i> = 751). Data from the single-arm atezolizumab trials BIRCH and FIR (<i>n</i> = 797) were used for external validation. Prognostic scores were categorized into low, intermediate-low, intermediate, intermediate-high, and high-risk prognostic groups. The primary outcome was overall survival (OS), with progression-free survival (PFS) secondary.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Pretreatment C-reactive protein (CRP) was the most predictive variable for OS. The prognostic tool was optimally defined by CRP, lactate dehydrogenase, derived neutrophil-to-lymphocyte ratio, albumin, PD-L1 expression, performance status, time since metastatic diagnosis, and metastatic site count. Prognostic groups had significantly different OS (<i>c</i>-statistic = 0.72), with median OS ranging from >24 to 3 months for the low- to high-risk groups. Performance was maintained on validation (<i>c</i> = 0.76). These findings were similar for PFS, with median PFS ranging from 5 months to 1 month for the low- to high-risk groups. Benefit of atezolizumab (vs. docetaxel) was greatest in the low-risk group (>3 months median OS improvement), with little benefit apparent for the highest risk group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A prognostic tool was developed and validated to identify patient groups with distinctly different survival following atezolizumab initiation for advanced NSCLC.</AbstractText><CopyrightInformation>©2020 American Association for Cancer Research.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hopkins</LastName><ForeName>Ashley M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia. ashley.hopkins@flinders.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kichenadasse</LastName><ForeName>Ganessan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Oncology, Flinders Medical Centre, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garrett-Mayer</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-4709-0333</Identifier><AffiliationInfo><Affiliation>American Society of Clinical Oncology, Alexandria, Virginia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karapetis</LastName><ForeName>Christos S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Oncology, Flinders Medical Centre, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Rowland</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sorich</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-1999-866X</Identifier><AffiliationInfo><Affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Cancer Res</MedlineTA><NlmUniqueID>9502500</NlmUniqueID><ISSNLinking>1078-0432</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>09</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>02</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32086341</ArticleId><ArticleId IdType="pii">1078-0432.CCR-19-2968</ArticleId><ArticleId IdType="doi">10.1158/1078-0432.CCR-19-2968</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>États-Unis</li></country><region><li>Virginie</li></region></list><tree><country name="Australie"><noRegion><name sortKey="Hopkins, Ashley M" sort="Hopkins, Ashley M" uniqKey="Hopkins A" first="Ashley M" last="Hopkins">Ashley M. Hopkins</name></noRegion><name sortKey="Karapetis, Christos S" sort="Karapetis, Christos S" uniqKey="Karapetis C" first="Christos S" last="Karapetis">Christos S. Karapetis</name><name sortKey="Karapetis, Christos S" sort="Karapetis, Christos S" uniqKey="Karapetis C" first="Christos S" last="Karapetis">Christos S. Karapetis</name><name sortKey="Kichenadasse, Ganessan" sort="Kichenadasse, Ganessan" uniqKey="Kichenadasse G" first="Ganessan" last="Kichenadasse">Ganessan Kichenadasse</name><name sortKey="Kichenadasse, Ganessan" sort="Kichenadasse, Ganessan" uniqKey="Kichenadasse G" first="Ganessan" last="Kichenadasse">Ganessan Kichenadasse</name><name sortKey="Rowland, Andrew" sort="Rowland, Andrew" uniqKey="Rowland A" first="Andrew" last="Rowland">Andrew Rowland</name><name sortKey="Sorich, Michael J" sort="Sorich, Michael J" uniqKey="Sorich M" first="Michael J" last="Sorich">Michael J. Sorich</name></country><country name="États-Unis"><region name="Virginie"><name sortKey="Garrett Mayer, Elizabeth" sort="Garrett Mayer, Elizabeth" uniqKey="Garrett Mayer E" first="Elizabeth" last="Garrett-Mayer">Elizabeth Garrett-Mayer</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000485 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000485 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PoplarV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32086341
|texte= Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32086341" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PoplarV1
| This area was generated with Dilib version V0.6.37. |  |